Physician profile
Brian Christopher Monize
NPI 1144596057
$4,416.80
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $1,846 · 2021: $676 · 2022: $112.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $698.70 | 2019-2021 | |
| Abbvie INC. | $565.09 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.54 | 2019-2021 | |
| Lilly USA, LLC | $296.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $286.99 | 2019-2021 | |
| Amgen INC. | $216.30 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $214.36 | 2019-2020 | |
| Amarin Pharma, INC. | $189.57 | 2019-2020 | |
| Insulet Corporation | $184.04 | 2019-2021 | |
| Valeritas, INC. | $172.30 | 2019 | |
| Amneal Pharmaceuticals LLC | $140.31 | 2019-2020 | |
| Mannkind Corporation | $122.22 | 2019-2021 | |
| Novo Nordisk INC | $121.53 | 2019-2021 | |
| Becton, Dickinson and Company | $118.34 | 2019-2020 | |
| Ibsa Pharma INC. | $112.46 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $104.25 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $81.74 | 2019 | |
| Shire North American Group INC | $74.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.92 | 2019 | |
| Lifescan, INC. | $55.61 | 2020-2021 | |
| Corcept Therapeutics | $53.45 | 2021 | |
| Radius Health, INC. | $49.65 | 2020 | |
| Abbott Laboratories | $37.06 | 2019-2022 | |
| Zealand Pharma US, INC. | $29.30 | 2020-2021 | |
| Csl Behring | $22.67 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Monize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.